Validation of an LC–MS/MS Method for Quantitative Analysis of the 5 Bioactive Components of Wuzhi Capsule in Human Plasma Samples
Authors:
- Haijun MiaoHMHaijun Miao
- Yunlei YunYYYunlei Yun
- Jingxian LiJLJingxian Li
- Xiaofeng QianXQXiaofeng Qian
- Rong WuRWRong Wu
- Wansheng ChenWCWansheng Chen
- 1 December 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 36 (6) , 781-788
Abstract
Wuzhi capsule (WZC) is an ethanol extract from the ripe fruit of Schisandra sphenanthera in traditional Chinese medicine that has long been used to treat viral and drug-induced hepatitis in China. The principal active components in WZC are Schisandra lignans. The clinical pharmacokinetics of these components in the form of an oral WZC preparation is unknown. To optimize the WZC dosage and develop WZC-related combination therapies, it is necessary to conduct a comprehensive pharmacokinetic study of the Schisandra lignans. A method was developed for simultaneous quantification of multiple bioactive lignans in WZC in human plasma through liquid-liquid extraction followed by multiple reaction monitoring liquid chromatography/tandem mass spectrometry with positive-mode electrospray ionization. The 5 bioactive constituents were separated by isocratic elution using a mobile phase consisting of acetonitrile, methanol, and 0.1% aqueous formic acid at a flow rate of 0.3 mL/min. The total run time was 3.5 minutes. All analytes showed good linearity over a wide concentration range with a lower limit of quantification at 0.5 ng/mL. Using this method, we determined the 5 bioactive lignans in WZC from human plasma simultaneously and performed a pharmacokinetic study on the Schisandra lignans in healthy volunteers. Owing to simplicity, quickness, high sensitivity, and selectivity, and a sufficient lower limit of detection of the new liquid chromatography/tandem mass spectrometry method, it may be used as a routine technique for clinical monitoring of WZC, and for understanding interactions between herbal and conventional drug therapies.Keywords
This publication has 19 references indexed in Scilit:
- Development of a Systematic Approach to Identify Metabolites for Herbal Homologs Based on Liquid Chromatography Hybrid Ion Trap Time-of-Flight Mass Spectrometry: Gender-Related Difference in Metabolism of S chisandra Lignans in RatsDrug Metabolism and Disposition, 2010
- A simple and sensitive HPLC method for the simultaneous determination of eight bioactive components and fingerprint analysis of Schisandra sphenantheraAnalytica Chimica Acta, 2010
- Simultaneous determination of five lignan constituents of Wuzhi capsule in rat plasma by LC–MS/MS: Application to pharmacokinetic studyJournal of Pharmaceutical and Biomedical Analysis, 2010
- Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteersBritish Journal of Clinical Pharmacology, 2007
- Effects of Schisandra Lignans on P-Glycoprotein-Mediated Drug Efflux in Human Intestinal Caco-2 CellsPlanta Medica, 2007
- Schisandrin B: A dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1Cancer Letters, 2007
- Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cellsBiochemical Pharmacology, 2006
- Determination of schizandrin in rat plasma by high-performance liquid chromatography–mass spectrometry and its application in rat pharmacokinetic studiesJournal of Chromatography B, 2005
- Schisandrin B—A novel inhibitor of P-glycoproteinBiochemical and Biophysical Research Communications, 2005
- IDENTIFICATION AND CHARACTERIZATION OF POTENT CYP3A4 INHIBITORS IN SCHISANDRA FRUIT EXTRACTDrug Metabolism and Disposition, 2004